A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors

Published:2013-08-20 Issue:3 Volume:76 Page:396-411
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Shah Rashmi R.¹,Roberts Samantha A.²,Shah Devron R.¹

Affiliation:

1. Rashmi Shah Consultancy Ltd; Gerrards Cross; UK

2. Friends of Cancer Research; Washington, DC; USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12085/fullpdf

Reference56 articles.

1. Regulatory review of novel therapeutics - comparison of three regulatory agencies;Downing;N Engl J Med,2012

2. Review of novel therapeutics by three regulatory agencies;Downing;N Engl J Med,2012

3. Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice;Trotta;J Clin Oncol,2011

4. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe;Roberts;Health Aff (Millwood),2011

5. Tufts Center for the Study of Drug Development U.S. offers patients faster, greater access to cancer drugs than Europe 2012 14 4 http://csdd.tufts.edu/files/uploads/08_-_july_10,_2012_-_cancer_drugs.pdf

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway;Journal of Pharmaceutical Policy and Practice;2024-06-04

2. Harmonizing regulatory market approval of products with high safety requirements: Evidence from the European pharmaceutical market;Health Economics;2024-03-15

3. New drug submissions in Canada and a comparison with the Food and Drug Administration and the European Medicines Agency: Cross-sectional analysis;PLOS ONE;2023-06-15

4. Regional Disparity in First-in-Class Anticancer Drug Development in the US, EU, and Japan;Biological and Pharmaceutical Bulletin;2023-05-01

5. A comparison of the Food and Drug Administration’s and Health Canada’s regulatory decisions about failed confirmatory trials for oncology drugs: an observational study;Journal of Pharmaceutical Policy and Practice;2021-10-28